These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 28175308)

  • 1. Population pharmacokinetics and dosing simulations of ceftazidime in critically ill patients receiving sustained low-efficiency dialysis.
    König C; Braune S; Roberts JA; Nierhaus A; Steinmetz OM; Baehr M; Frey OR; Langebrake C; Kluge S
    J Antimicrob Chemother; 2017 May; 72(5):1433-1440. PubMed ID: 28175308
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Piperacillin Population Pharmacokinetics in Critically Ill Adults During Sustained Low-Efficiency Dialysis.
    Kanji S; Roberts JA; Xie J; Alobaid A; Zelenitsky S; Hiremath S; Zhang G; Watpool I; Porteous R; Patel R
    Ann Pharmacother; 2018 Oct; 52(10):965-973. PubMed ID: 29730948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of meropenem in septic patients on sustained low-efficiency dialysis: a population pharmacokinetic study.
    Braune S; König C; Roberts JA; Nierhaus A; Steinmetz O; Baehr M; Kluge S; Langebrake C
    Crit Care; 2018 Jan; 22(1):25. PubMed ID: 29382394
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic and Pharmacodynamic Analysis of Ceftazidime/Avibactam in Critically Ill Patients.
    Stein GE; Smith CL; Scharmen A; Kidd JM; Cooper C; Kuti J; Mitra S; Nicolau DP; Havlichek DH
    Surg Infect (Larchmt); 2019 Jan; 20(1):55-61. PubMed ID: 30351195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vancomycin Population Pharmacokinetics in Critically Ill Adults During Sustained Low-Efficiency Dialysis.
    Kanji S; Roberts JA; Xie J; Zelenitsky S; Hiremath S; Zhang G; Watpool I; Porteous R; Patel R
    Clin Pharmacokinet; 2020 Mar; 59(3):327-334. PubMed ID: 31471789
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacodynamic target attainment for various ceftazidime dosing schemes in high-flux hemodialysis.
    Loo AS; Neely M; Anderson EJ; Ghossein C; McLaughlin MM; Scheetz MH
    Antimicrob Agents Chemother; 2013 Dec; 57(12):5854-9. PubMed ID: 24018264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic-Pharmacodynamic Target Attainment Analyses To Determine Optimal Dosing of Ceftazidime-Avibactam for the Treatment of Acute Pulmonary Exacerbations in Patients with Cystic Fibrosis.
    Bensman TJ; Wang J; Jayne J; Fukushima L; Rao AP; D'Argenio DZ; Beringer PM
    Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28784670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of piperacillin in critically ill patients with acute kidney injury receiving sustained low-efficiency diafiltration.
    Sinnollareddy MG; Roberts MS; Lipman J; Peake SL; Roberts JA
    J Antimicrob Chemother; 2018 Jun; 73(6):1647-1650. PubMed ID: 29506150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population Pharmacokinetics of Doripenem in Critically Ill Patients with Sepsis in a Malaysian Intensive Care Unit.
    Abdul-Aziz MH; Abd Rahman AN; Mat-Nor MB; Sulaiman H; Wallis SC; Lipman J; Roberts JA; Staatz CE
    Antimicrob Agents Chemother; 2016 Jan; 60(1):206-14. PubMed ID: 26482304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimized meropenem dosage regimens using a pharmacokinetic/pharmacodynamic population approach in patients undergoing continuous venovenous haemodiafiltration with high-adsorbent membrane.
    Padullés Zamora A; Juvany Roig R; Leiva Badosa E; Sabater Riera J; Pérez Fernández XL; Cárdenas Campos P; Rigo Bonin R; Alía Ramos P; Tubau Quintano F; Sospedra Martinez E; Colom Codina H
    J Antimicrob Chemother; 2019 Oct; 74(10):2979-2983. PubMed ID: 31335959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of Monte Carlo Simulations to Determine Optimal Carbapenem Dosing in Critically Ill Patients Receiving Prolonged Intermittent Renal Replacement Therapy.
    Lewis SJ; Kays MB; Mueller BA
    J Clin Pharmacol; 2016 Oct; 56(10):1277-87. PubMed ID: 26919659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis.
    Roberts JA; Kirkpatrick CM; Roberts MS; Dalley AJ; Lipman J
    Int J Antimicrob Agents; 2010 Feb; 35(2):156-63. PubMed ID: 20018492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A retrospective analysis using Monte Carlo simulation to evaluate recommended ceftazidime dosing regimens in healthy volunteers, patients with cystic fibrosis, and patients in the intensive care unit.
    Mouton JW; Punt N; Vinks AA
    Clin Ther; 2005 Jun; 27(6):762-72. PubMed ID: 16117983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population pharmacokinetics and Monte Carlo dosing simulations of meropenem during the early phase of severe sepsis and septic shock in critically ill patients in intensive care units.
    Jaruratanasirikul S; Thengyai S; Wongpoowarak W; Wattanavijitkul T; Tangkitwanitjaroen K; Sukarnjanaset W; Jullangkoon M; Samaeng M
    Antimicrob Agents Chemother; 2015; 59(6):2995-3001. PubMed ID: 25753628
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Meropenem removal in critically ill patients undergoing sustained low-efficiency dialysis (SLED).
    Deshpande P; Chen J; Gofran A; Murea M; Golestaneh L
    Nephrol Dial Transplant; 2010 Aug; 25(8):2632-6. PubMed ID: 20181801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population pharmacokinetics and pharmacodynamics of piperacillin in critically ill patients during the early phase of sepsis.
    Sukarnjanaset W; Jaruratanasirikul S; Wattanavijitkul T
    J Pharmacokinet Pharmacodyn; 2019 Jun; 46(3):251-261. PubMed ID: 30963365
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population Pharmacokinetics of Unbound Ceftolozane and Tazobactam in Critically Ill Patients without Renal Dysfunction.
    Sime FB; Lassig-Smith M; Starr T; Stuart J; Pandey S; Parker SL; Wallis SC; Lipman J; Roberts JA
    Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31358583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population pharmacokinetics of vancomycin in critically ill patients receiving prolonged intermittent renal replacement therapy.
    Economou CJP; Kielstein JT; Czock D; Xie J; Field J; Richards B; Tallott M; Visser A; Koenig C; Hafer C; Schmidt JJ; Lipman J; Roberts JA
    Int J Antimicrob Agents; 2018 Aug; 52(2):151-157. PubMed ID: 29526606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. What is the optimal loading dose of broad-spectrum β-lactam antibiotics in septic patients? Results from pharmacokinetic simulation modelling.
    Delattre IK; Hites M; Laterre PF; Dugernier T; Spapen H; Wallemacq PE; Jacobs F; Taccone FS
    Int J Antimicrob Agents; 2020 Oct; 56(4):106113. PubMed ID: 32721604
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population pharmacokinetics and target attainment of ciprofloxacin in critically ill patients.
    Abdulla A; Rogouti O; Hunfeld NGM; Endeman H; Dijkstra A; van Gelder T; Muller AE; de Winter BCM; Koch BCP
    Eur J Clin Pharmacol; 2020 Jul; 76(7):957-967. PubMed ID: 32307575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.